EXHIBITORS
Dechra Veterinary Products ...................16089/17089/ 17091
7015 College Blvd Suite 525
Submit your completed Trade Show Bingo card at the AAEP booth and receive a $10 General Store gift certifi cate and be entered in daily drawings for prizes.
Altren
(altrenogest) Solution 0.22% contains the active synthetic progestin, altrenogest. The chemical name is
DESCRIPTION: Altren®
structure is: ® (altrenogest)
SOLUTION 0.22% (2.2 mg/mL) CAUTION:
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
DOSAGE CHART:
in Pounds 770
880
1100 1210
in mL 7
8
10 11
WHICH MARES WILL RESPOND TO ALTREN® (altrenogest) SOLUTION 0.22%:
depended on the level of ovarian activity when treatment cycles during the breeding season will be suppressed
days following treatment and continue to cycle normally. Mares in winter anestrus with small follicles continued withdrawal.
Each mL of Altren®
ACTIONS: Altren®
(altrenogest) Solution 0.22% contains 2.2 mg of altrenogest in an oil solution. (altrenogest) Solution 0.22% produces a progestational effect in mares.
INDICATIONS: Altren®
(altrenogest) Solution 0.22% is indicated to suppress estrus in mares. Suppression of estrus allows for a predictable occurrence of estrus following drug withdrawal. This facilitates the attainment of regular cyclicity during the transition from winter anestrus to the physiological breeding season. Suppression of estrus will also facilitate management of prolonged estrus conditions. Suppression of estrus may be used to facilitate scheduled breeding during the physiological breeding season.
CONTRAINDICATIONS: Altren®
(altrenogest) Solution 0.22% is contraindicated for use in mares having a previous or current history of
endometritis). Natural or synthetic gestagen therapy may instances.
PRECAUTIONS: Various synthetic progestins, including altrenogest, when administered to rats during the embryogenic stage of pregnancy at doses manyfold greater than the recom
masculinization of the female genitalia. DOSAGE AND DIRECTIONS:
While wearing protective gloves, remove shipping cap and seal; replace with enclosed plastic dispensing cap. Remove cover from bottle dispensing tip and connect luer lock syringe (without needle). Draw out appropriate volume of Altren®
for 15 consecutive days. Administer solution directly on the base of the mare’s tongue or on the mare’s usual grain ration. Replace cover on bottle dispensing tip
cause the syringe to stick; therefore, replace syringe as necessary.
Response in mares in the transition phase between winter anestrus and the summer breeding season depended on the degree of follicular activity. Mares with inactive ovaries and small follicles failed to respond
proportion of mares with ovarian follicles 20 mm or (100%).
effective for suppressing the prolonged estrus behavior frequently observed in mares during the transition period (February, March and April). In addition, a high proportion of these mares responded with regular estrus cycles
SPECIFIC USES FOR ALTREN® SOLUTION 0.22%:
(altrenogest)
SUPPRESSION OF ESTRUS TO: 1. Facilitate attainment of regular cycles during the tran sition period from winter anestrus to the physiological breeding season. To facilitate attainment of regular cycles during the transition phase, mares should be
Estrus in mares with inactive ovaries (no follicles greater than 20 mm in diameter) will be suppressed but these mares may not begin regular cycles follow ing treatment. However, mares with active ovaries (follicles greater than 20 mm in diameter) frequently
prolonged estrus during the transition period. Estrus havioral estrus either early or late during the transition
on the level of ovarian activity. The mares with greater ovarian activity initiate regular cycles and conceive sooner than the inactive mares. Altren®
(altrenogest)
Solution 0.22% may be administered early in the tran sition period to suppress estrus in mares with inactive ovaries to aid in the management of these mares or to mares later in the transition period with active ovaries to prepare and schedule the mare for breeding.
solution. (Note: Do not remove syringe
while bottle is inverted as spillage may result.) Detach syringe and administer solution orally at the rate of 1 mL
physiological breeding season. To permit scheduled breeding, mares which are regularly cycling or which have active ovarian function should be given Altren® (altrenogest) Solution 0.22% daily for 15 consecu tive days beginning 20 days before the date of the planned estrus. Ovulation will occur 5 to 7 days fol
mares. Breeding should follow usual procedures for mares in estrus. Mares may be regulated and scheduled either individually or in groups.
• colt offspring of treated and control mares reached weeks respectively).
• stallion offspring from treated and control mares showed no differences in seminal volume, spermatozoal concentration, spermatozoal motility, and total sperm per ejaculate.
• stallion offspring from treated and control mares
• testicular characteristics (scrotal width, testis weight, parenchymal weight, epididymal weight and height, testicular height, width & length) were the same between stallion offspring of treated and control mares.
REFERENCES: Safety of Altrenogest in Pregnant Mares and on Health
Overland Park, KS 66211 Phone: (866) 933-2472 Email:
us.dechratradeshows@
dechra.com
www.dechra-us.com (See our ad on page 67.)
Dechra Veterinary Products’ equine portfolio includes Osphos® injection), Orthokine®
(clodronate vet irap 10 and ADDITIONAL INFORMATION:
untreated control mares. Treated mares received 2 mL dosage recommended for estrus suppression) from following data:
size was increased.
2. Filly offspring from treated mares had shorter interval untreated mare counterparts.
performance between treated and untreated animals (mares & their respective offspring) measuring the following parameters:
only. cycle and second to third cycle, mares only.
• follicle size, mares only. • at 50 days gestation, pregnancy rate in treated
INFORMATION FOR HANDLERS: WARNING: Altren®
(altrenogest) Solution 0.22% is
readily absorbed by the skin. Skin contact must be avoided; protective gloves must be worn when handling this product.
Effects of Overexposure
from data available on other products of the same pharmacological class that have been used in humans. Effects anticipated are due to the progestational activity of altrenogest.
untoward effects such as disruption of the menstrual cycle, uterine or abdominal cramping, increased or decreased uterine bleeding, prolongation of pregnancy and headaches. The oil base may also cause complica tions if swallowed.
In addition, the list of people who should not handle this product (see below) is based upon the known effects of progestins used in humans on a chronic basis.
PEOPLE WHO SHOULD NOT HANDLE THIS PRODUCT:
1. Women who are or suspect they are pregnant.
2. Anyone with thrombophlebitis or thromboembolic disorders or with a history of these events. disease. breast.
neoplasia. 6. Women with undiagnosed vaginal bleeding.
7. People with benign or malignant tumors which developed during the use of oral contraceptives or
8. Anyone with liver dysfunction or disease. Accidental Exposure
Altrenogest is readily absorbed from contact with the skin. In addition, this oil based product can penetrate porous gloves. Altrenogest should not penetrate intact rubber or impervious gloves; however, if there is leakage (i.e., pinhole, spillage, etc.), the contaminated area covered by such occlusive materials may have increased absorption. The following measures are recommended in
Reproductive Performance of Offspring from Mares Administered Altrenogest During Gestation.
WARNING:
For oral use in horses only. Keep this and all other medications out of the reach of children. Do not use in horses intended for human consumption.
HUMAN WARNINGS: Skin contact must be avoided as Altren® (altrenogest)
Solution 0.22% is readily absorbed through unbroken skin. Protective gloves must be worn by all persons handling this product. Pregnant women or women who suspect they are pregnant should not handle Altren®
(altrenogest) Solution 0.22%. Women of child bearing age should exercise extreme caution when handling this product. Accidental absorption could lead to a disruption of the menstrual cycle or prolongation of pregnancy. Direct contact with the skin should therefore be avoided. Accidental spillage on the skin should be washed off immediately with soap and water.
Store upright at or below 25° C (77° F). Reclose tightly.
HOW SUPPLIED: Altren® Each mL contains 2.2 mg altrenogest in an oil solution. Available in 150 mL and 1000 mL plastic bottles.
Manufactured by:
Aurora Pharmaceutical, Inc. Approved by FDA
60, and Osteokine® offers Equidone® Vetivex®
(PRP). Dechra also Gel (domperidone), the
line of parenteral fluids, Phycox® EQ joint health supplements, and a comprehensive line of topical derma- tologic products. The recent additions of ProVet APC™
(Autologous Platelet Concentrate) system, Rompun® (xylazine
injection), Butorphanol Tartrate Injection, Isoflurane, USP Inhalant Anesthetic, SucroMate® and Zimeta®
Equine (deslorelin acetate), (dipyrone injection) further
expand Dechra’s equine offerings.
15 minutes. Get medical attention. If Swallowed: Do not induce vomiting. Altren®
(altreno
gest) Solution 0.22% contains an oil. Call a physician. Vomiting should be supervised by a physician because of possible pulmonary damage via aspiration of the oil base. If possible, bring the container and labeling to the physician.
52
AAEP | 68th Annual Convention 2022 San Antonio
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116
